Description 
Application
B-hTROP2 CT26.WT cells have the capability to establish tumors in vivo and can be used for efficacy studies.
Targeting strategy
Gene targeting strategy for B-hTROP2 CT26.WT cells. Expression cassettes containing the exogenous promoter and human TROP2 CDS were randomly inserted into the genome of CT26.WT cells that do not express the mouse TROP2.
Protein expression analysis 

Tumor growth curve & Body weight changes

Subcutaneous homograft tumor growth of B-hTROP2 CT26.WT cells. B-hTROP2 CT26.WT cells (1x10⁵) and wild-type CT26.WT cells (1x10⁵) were subcutaneously implanted into BALB/c mice (female, 8-week-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². As shown in panel A, B-hTROP2 CT26.WT cells were able to establish tumors in vivo and can be used for efficacy studies.

Protein expression analysis of tumor cells

B-hTROP2 CT26.WT cells were subcutaneously transplanted into BALB/c mice (n=6), and on 24 days post inoculation, tumor cells were harvested and assessed for human TROP2 expression by flow cytometry. As shown, human TROP2 was highly expressed on the surface of tumor cells. Therefore, B-hTROP2 CT26.WT cells can be used for in vivo efficacy studies of novel TROP2 therapeutics.